Frankie Fattorini

1 week ago | pharmaceutical-technology.com | Frankie Fattorini

Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC. Pfizer’s Braftovi cur the risk of death in first-line combination therapy for BRAF V600E mCRC. Photo by SOPA Images / LightRocket via Getty Images.

1 week ago | clinicaltrialsarena.com | Frankie Fattorini

Representatives of industry and regulation will meet in June to discuss paths forward for the UK’s clinical trials sector following its recent reform and revitalisation. Delegates convene in London on 10–11 June at the 12th annual Outsourcing in Clinical Trials UK & Ireland conference to explore the challenges, innovations, and opportunities of trial outsourcing.

2 weeks ago | pharmaceutical-technology.com | Frankie Fattorini

Potential US pharma import tariffs could raise prices, stifle innovation, and revolutionise how the industry produces drugs. Biopharma braces for Trump’s tariffs aimed at bringing manufacturing back to the US. Photo by Bloomberg/Bloomberg via Getty Images. As President Trump continues to signal import tariffs on pharmaceuticals to bolster US manufacturing, experts warn this could hike costs and crush biotech, but also spur reconsideration of biopharma production.

1 month ago | pharmaceutical-technology.com | Frankie Fattorini

The slowdown in IPOs following tariff-associated turbulence and FDA reorganisation will soon pass, say industry investors. Panellists Dirk Kersten, Max Klement, Alastair Kilgour, and John Rudy at LSX World Congress 2025 projected an eventual return of biotech IPOs following the current drought. Credit: Frankie Fattorini / GlobalData.

1 month ago | pharmaceutical-technology.com | Frankie Fattorini

Funding troubles and innovation responsibilities are falling more heavily on emerging biotechs under strain from US developments. Hard times are ahead for biotechs as the funding drought is set to worsen, with increased investor uncertainty following Trump tariffs and FDA cuts, said Cody Powers, partner at ZS Associates, speaking at the LSX World Congress 2025. Credit: Frankie Fattorini / GlobalData.